Francine R Dembitzer, MD

Research

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:11

Article:15

Letter:2

Recent Artifacts

• Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
• Atypical lymphocyte morphology in SARS-CoV-2 infection
• Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy
• Increased RNA expression of von Willebrand factor gene is associated with infiltrating lobular breast cancer and normal PAM50 subtype
• In primary glioblastoma fewer tumor copy number segments of the F13A1 gene are associated with poorer survival
• Surgical pathology of early stage non-small cell lung carcinoma
• Impact of histologic subtyping on outcome in lobar vs sublobar resections for lung cancer: A pilot study
• Atypical Chédiak-Higashi syndrome with attenuated phenotype: Three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease
• gC1qR Expression in Normal and Pathologic Human Tissues: Differential Expression in Tissues of Epithelial and Mesenchymal Origin
• Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Dembitzer did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.